CompletedPhase 3

A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis

Egypt36 participantsStarted 2023-03-01

Plain-language summary

This study aimed to assess the efficacy of MEBO® in the treatment of already established oral mucositis. This is a randomized controlled clinical trial. The study included 36 patients with established oral mucositis, divided into two groups. Patients were randomly allocated to either receive topically applied MEBO® ointment or Benzydamine Hydrochloride (Tantum Verde) mouthwash three times a day for two weeks. We assessed the World Health Organization mucositis score (WHO), the Oral Mucositis Assessment Scale (OMAS), and the Patient-Reported Oral Mucositis Symptom (PROMS) score at baseline, and after one and two weeks.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who later on during radiotherapy developed oral mucositis with a severity of WHO score II or more and were over 18 years were then included in the study and allocated to one of the treatment groups . Exclusion Criteria: * We excluded patients who were receiving any prophylactic agents and/or corticosteroids and those who would not sign the informed consent.

What they're measuring

WHO oral mucositis score

Timeframe: We assessed patients for the three outcomes at baseline, one week and at the end of the study period which is two weeks

Trial details

NCT IDNCT07186114

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-14

View on ClinicalTrials.gov More Oral Mucositis (Ulcerative) Due to Radiation trials